Telix Pharmaceuticals Ltd has released a press release.
Appendix 4E and 2025 Annual Report
Filed with ASX ·
Watch Telix Pharmaceuticals' latest callTelix Pharmaceuticals (ASX:TLX) Q2 2026 Earnings Call · Replay · Aug 20Read the transcript of Telix Pharmaceuticals (ASX:TLX) Q2 2026 Earnings Call6ix hasn’t read this filing yet.
Telix Pharmaceuticals Limited on 6ix
In the deck
Story so far
Earlier from Telix Pharmaceuticals
- 2025 Full Year Results Announcement
- Telix Submits European Marketing Authorization Application for TLX101-Px for Brain Cancer Imaging
- Telix Submits EU MAA for TLX101-Px Brain Cancer Imaging
- Telix Full Year Results 2025 Investor Webcast Notification
- First Patient Dosed in Pivotal Phase 3 Study of TLX591-Px (Illuccix®) for Prostate Cancer Imaging in Japanese Patients
Later from Telix Pharmaceuticals
- 2025 Full Year Results Presentation
- Telix to Participate in Oppenheimer and TD Cowen Conferences
- Telix Joins Forces with University Hospital Essen on PROMISE-PET: Optimizing Patient Management through AI-enabled PSMA-PET Imaging
- Investor Education Webinar
- ProstACT Global Phase 3 (Part 1) Achieves Primary Objectives
Follow Telix Pharmaceuticals into a list and get an email when it puts out news.
Follow Telix Pharmaceuticals